Editas Medicine, Inc. (EDIT) DCF Valuation

Editas Medicine, Inc. (EDIT) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Editas Medicine, Inc. (EDIT) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Evaluate Editas Medicine, Inc.'s (EDIT) financial prospects like an expert! This (EDIT) DCF Calculator provides pre-filled financial data and full flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your predictions.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 20.5 90.7 25.5 19.7 78.1 98.7 124.7 157.5 199.0 251.4
Revenue Growth, % 0 341.93 -71.85 -22.83 296.32 26.33 26.33 26.33 26.33 26.33
EBITDA -138.1 -130.9 -188.1 -219.6 -163.1 -98.7 -124.7 -157.5 -199.0 -251.4
EBITDA, % -672.6 -144.25 -736.35 -1114.11 -208.8 -100 -100 -100 -100 -100
Depreciation 2.8 4.0 5.1 6.3 6.1 15.4 19.4 24.5 31.0 39.1
Depreciation, % 13.78 4.36 19.78 32.15 7.76 15.57 15.57 15.57 15.57 15.57
EBIT -140.9 -134.8 -193.1 -226.0 -169.2 -98.7 -124.7 -157.5 -199.0 -251.4
EBIT, % -686.39 -148.61 -756.13 -1146.26 -216.56 -100 -100 -100 -100 -100
Total Cash 457.1 511.8 619.9 437.4 323.1 98.7 124.7 157.5 199.0 251.4
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .4 6.0 .3 5.1 10.2
Account Receivables, % 2.04 6.67 1.05 26.1 13.04
Inventories .0 -109.7 -120.1 -93.1 .0 -59.2 -74.8 -94.5 -119.4 -150.8
Inventories, % 0 -120.87 -470.05 -472.29 0 -60 -60 -60 -60 -60
Accounts Payable 5.8 6.4 5.1 9.5 8.3 22.5 28.5 36.0 45.4 57.4
Accounts Payable, % 28.46 7.06 19.77 48.25 10.58 22.83 22.83 22.83 22.83 22.83
Capital Expenditure -6.2 -7.2 -8.0 -4.1 -4.7 -19.0 -24.0 -30.3 -38.2 -48.3
Capital Expenditure, % -30.04 -7.89 -31.23 -20.89 -6.04 -19.22 -19.22 -19.22 -19.22 -19.22
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -130.1 -127.2 -185.7 -209.5 -169.2 -93.9 -118.6 -149.8 -189.2 -239.1
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -128.0 -25.8 -173.8 -234.6 -267.2 -23.5 -104.1 -131.6 -166.2 -210.0
WACC, % 11.13 11.15 11.18 11.13 11.23 11.16 11.16 11.16 11.16 11.16
PV UFCF
SUM PV UFCF -433.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -214
Terminal Value -2,337
Present Terminal Value -1,377
Enterprise Value -1,811
Net Debt -87
Equity Value -1,723
Diluted Shares Outstanding, MM 76
Equity Value Per Share -22.69

What You Will Receive

  • Comprehensive Financial Model: Editas Medicine’s actual data facilitates accurate DCF valuation.
  • Complete Forecast Control: Modify revenue growth, margins, WACC, and other essential drivers.
  • Real-Time Calculations: Automatic updates provide immediate results as adjustments are made.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
  • Flexible and Reusable: Designed for adaptability, allowing repeated application for in-depth forecasts.

Key Features

  • Comprehensive Data: Editas Medicine's historical financial reports and pre-filled projections.
  • Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Insights: View Editas Medicine's intrinsic value update instantly.
  • Intuitive Visuals: Dashboard graphs illustrate valuation outcomes and essential metrics.
  • Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.

How It Works

  • Download: Obtain the pre-built Excel file containing Editas Medicine, Inc.'s (EDIT) financial data.
  • Customize: Modify forecasts, such as revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Develop various projections and instantly compare results.
  • Make Decisions: Leverage the valuation outcomes to inform your investment strategy.

Why Choose Editas Medicine, Inc. (EDIT)?

  • Innovative Solutions: Pioneering gene-editing technology to transform medicine.
  • Expert Team: Led by industry leaders dedicated to advancing genetic research.
  • Robust Pipeline: A diverse portfolio of therapies targeting serious diseases.
  • Commitment to Quality: Adhering to the highest standards in research and development.
  • Strong Partnerships: Collaborating with top organizations to enhance scientific progress.

Who Should Use This Product?

  • Professional Investors: Develop comprehensive and accurate valuation models for assessing investments in Editas Medicine, Inc. (EDIT).
  • Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
  • Consultants and Advisors: Deliver precise valuation insights to clients interested in Editas Medicine, Inc. (EDIT).
  • Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
  • Biotech Enthusiasts: Gain insights into how biotechnology firms like Editas Medicine, Inc. (EDIT) are assessed in the market.

What the Template Contains

  • Preloaded EDIT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.